vs
STANDARD BIOTOOLS INC.（LAB）与SMITH MIDLAND CORP（SMID）财务数据对比。点击上方公司名可切换其他公司
SMITH MIDLAND CORP的季度营收约是STANDARD BIOTOOLS INC.的1.2倍（$23.1M vs $19.6M），SMITH MIDLAND CORP净利率更高（9.2% vs -177.4%，领先186.6%），SMITH MIDLAND CORP同比增速更快（24.7% vs -11.5%），过去两年SMITH MIDLAND CORP的营收复合增速更高（17.4% vs -12.2%）
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
Smith Midland Corp是一家预制混凝土产品专业制造商，核心产品线包括公路安全护栏、隔音墙、建筑预制面板及雨水管理系统，主要服务北美市场，为各类基建、商用、住宅及工业建筑项目提供耐用可持续的建筑解决方案。
LAB vs SMID — 直观对比
营收规模更大
SMID
是对方的1.2倍
$19.6M
营收增速更快
SMID
高出36.2%
-11.5%
净利率更高
SMID
高出186.6%
-177.4%
两年增速更快
SMID
近两年复合增速
-12.2%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $19.6M | $23.1M |
| 净利润 | $-34.7M | $2.1M |
| 毛利率 | 48.5% | 57.5% |
| 营业利润率 | -168.5% | 37.8% |
| 净利率 | -177.4% | 9.2% |
| 营收同比 | -11.5% | 24.7% |
| 净利润同比 | -28.8% | 52.5% |
| 每股收益（稀释后） | $-0.09 | $0.41 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LABSMID
| Q4 25 | — | $23.1M | ||
| Q3 25 | $19.6M | $21.5M | ||
| Q2 25 | $21.8M | $26.2M | ||
| Q1 25 | $40.8M | $22.7M | ||
| Q4 24 | — | $18.5M | ||
| Q3 24 | $22.1M | $23.6M | ||
| Q2 24 | $22.5M | $19.6M | ||
| Q1 24 | $45.5M | $16.8M |
净利润LABSMID
| Q4 25 | — | $2.1M | ||
| Q3 25 | $-34.7M | $2.9M | ||
| Q2 25 | $-33.5M | $4.2M | ||
| Q1 25 | $-26.0M | $3.3M | ||
| Q4 24 | — | $1.4M | ||
| Q3 24 | $-26.9M | $3.1M | ||
| Q2 24 | $-45.7M | $2.0M | ||
| Q1 24 | $-32.2M | $1.1M |
毛利率LABSMID
| Q4 25 | — | 57.5% | ||
| Q3 25 | 48.5% | 26.8% | ||
| Q2 25 | 48.8% | 0.0% | ||
| Q1 25 | 48.4% | 30.7% | ||
| Q4 24 | — | 51.4% | ||
| Q3 24 | 54.9% | 27.9% | ||
| Q2 24 | 46.1% | 0.0% | ||
| Q1 24 | 53.1% | 23.3% |
营业利润率LABSMID
| Q4 25 | — | 37.8% | ||
| Q3 25 | -168.5% | 18.0% | ||
| Q2 25 | -118.1% | 0.0% | ||
| Q1 25 | -80.8% | 19.3% | ||
| Q4 24 | — | 24.5% | ||
| Q3 24 | -120.9% | 16.3% | ||
| Q2 24 | -134.5% | 0.0% | ||
| Q1 24 | -132.2% | 9.0% |
净利率LABSMID
| Q4 25 | — | 9.2% | ||
| Q3 25 | -177.4% | 13.4% | ||
| Q2 25 | -153.7% | 15.9% | ||
| Q1 25 | -63.8% | 14.7% | ||
| Q4 24 | — | 7.5% | ||
| Q3 24 | -122.0% | 13.4% | ||
| Q2 24 | -203.3% | 10.1% | ||
| Q1 24 | -70.6% | 6.8% |
每股收益（稀释后）LABSMID
| Q4 25 | — | $0.41 | ||
| Q3 25 | $-0.09 | $0.54 | ||
| Q2 25 | $-0.09 | $0.79 | ||
| Q1 25 | $-0.07 | $0.62 | ||
| Q4 24 | — | $0.28 | ||
| Q3 24 | $-0.07 | $0.59 | ||
| Q2 24 | $-0.12 | $0.37 | ||
| Q1 24 | $-0.27 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $129.4M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $399.7M | $54.3M |
| 总资产 | $539.6M | $87.7M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LABSMID
| Q4 25 | — | — | ||
| Q3 25 | $129.4M | — | ||
| Q2 25 | $158.6M | — | ||
| Q1 25 | $150.9M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $210.6M | — | ||
| Q2 24 | $269.8M | — | ||
| Q1 24 | $287.1M | — |
总债务LABSMID
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $55.2M | — | ||
| Q2 24 | $55.1M | — | ||
| Q1 24 | $55.0M | — |
股东权益LABSMID
| Q4 25 | — | $54.3M | ||
| Q3 25 | $399.7M | $52.1M | ||
| Q2 25 | $424.5M | $49.2M | ||
| Q1 25 | $454.6M | $45.1M | ||
| Q4 24 | — | $41.7M | ||
| Q3 24 | $489.3M | $40.3M | ||
| Q2 24 | $510.3M | $37.2M | ||
| Q1 24 | $577.3M | $35.3M |
总资产LABSMID
| Q4 25 | — | $87.7M | ||
| Q3 25 | $539.6M | $85.4M | ||
| Q2 25 | $557.0M | $81.2K | ||
| Q1 25 | $579.6M | $74.7M | ||
| Q4 24 | — | $68.0M | ||
| Q3 24 | $681.5M | $66.6M | ||
| Q2 24 | $708.7M | $64.0M | ||
| Q1 24 | $777.7M | $64.9M |
负债/权益比LABSMID
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.11× | — | ||
| Q2 24 | 0.11× | — | ||
| Q1 24 | 0.10× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-23.1M | — |
| 自由现金流率自由现金流/营收 | -118.1% | — |
| 资本支出强度资本支出/营收 | 4.5% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-111.1M | — |
8季度趋势，按日历期对齐
经营现金流LABSMID
| Q4 25 | — | — | ||
| Q3 25 | $-22.2M | $11.7M | ||
| Q2 25 | $-20.7M | — | ||
| Q1 25 | $-30.3M | $2.2M | ||
| Q4 24 | — | $-645.0K | ||
| Q3 24 | $-27.9M | $3.9M | ||
| Q2 24 | $-39.0M | $2.7M | ||
| Q1 24 | $-62.5M | $-777.0K |
自由现金流LABSMID
| Q4 25 | — | — | ||
| Q3 25 | $-23.1M | $6.3M | ||
| Q2 25 | $-22.6M | — | ||
| Q1 25 | $-35.3M | $1.6M | ||
| Q4 24 | — | $-1.3M | ||
| Q3 24 | $-30.1M | $1.8M | ||
| Q2 24 | $-41.0M | $998.0K | ||
| Q1 24 | $-63.3M | $-2.6M |
自由现金流率LABSMID
| Q4 25 | — | — | ||
| Q3 25 | -118.1% | 29.5% | ||
| Q2 25 | -103.6% | — | ||
| Q1 25 | -86.6% | 7.1% | ||
| Q4 24 | — | -7.0% | ||
| Q3 24 | -136.4% | 7.8% | ||
| Q2 24 | -182.2% | 5.1% | ||
| Q1 24 | -138.9% | -15.3% |
资本支出强度LABSMID
| Q4 25 | — | — | ||
| Q3 25 | 4.5% | 25.1% | ||
| Q2 25 | 8.7% | — | ||
| Q1 25 | 12.4% | 2.6% | ||
| Q4 24 | — | 3.6% | ||
| Q3 24 | 10.2% | 8.6% | ||
| Q2 24 | 8.6% | 8.7% | ||
| Q1 24 | 1.7% | 10.7% |
现金转化率LABSMID
| Q4 25 | — | — | ||
| Q3 25 | — | 4.07× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.67× | ||
| Q4 24 | — | -0.46× | ||
| Q3 24 | — | 1.23× | ||
| Q2 24 | — | 1.37× | ||
| Q1 24 | — | -0.68× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
SMID
| Product Sales | $13.8M | 60% |
| Service Revenue | $9.3M | 40% |
